0001209191-23-031634.txt : 20230522
0001209191-23-031634.hdr.sgml : 20230522
20230522214011
ACCESSION NUMBER: 0001209191-23-031634
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230217
FILED AS OF DATE: 20230522
DATE AS OF CHANGE: 20230522
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yea Christopher
CENTRAL INDEX KEY: 0001691102
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 23946399
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE, BUILDING 200
STREET 2: SUITE 2203
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200915291
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (857) 999-0075
MAIL ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Therapeutics, Inc.
DATE OF NAME CHANGE: 20140916
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0407
4/A
2023-02-17
2023-02-23
0
0001348911
KalVista Pharmaceuticals, Inc.
KALV
0001691102
Yea Christopher
C/O KALVISTA PHARMACEUTICALS, INC
55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE
MA
02142
0
1
0
0
Chief Development Officer
0
Restricted Stock Unit
2023-02-17
4
M
0
2430
0.00
D
Common Stock
2430
26736
D
The original Form 4 filed on February 23, 2023, is being amended by this Form 4 amendment solely to correct an administrative error, which mis-reported the vesting schedule and the restricted stock unit as a performance restricted stock unit.
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 17, 2022, subject to continued service through each vesting date.
/s/ Benjamin L. Palleiko, Attorney-in-Fact
2023-05-22